Proxopheline, eye drops 1.5 ml 5 pcs

Pharmacotherapeutic group: antiglaucoma.

ATX code: S01EX.

Pharmacological properties
Combination drug, has anti-glaucoma effect. Clonidine and butylaminohydroxypropoxyphenoxymethyl methyloxadiazole reduce intraocular pressure by reducing aqueous humor production and increasing its outflow. The effect occurs 15-30 min after instillation, peaks in 2-6 hours and lasts for 24 hours. It has no effect on accommodation, refraction and pupil size.

Indications

Proxofelin is used to reduce intraocular pressure in patients with various forms of glaucoma (open-angle, closed-angle, secondary) in case of insufficient effect of monotherapy with proxodolol or clonidine. For angle-closure glaucoma, the drug is used in combination with miotics.

Pharmacological effect

Pharmacotherapeutic group: antiglaucoma agent.

ATX code: S01EX.

Pharmacological properties

The combined drug has an antiglaucoma effect. Clonidine and butylaminohydroxypropoxyphenoxymethyl methyloxadiazole reduce intraocular pressure by reducing the production of aqueous humor and increasing its outflow. The effect occurs 15-30 minutes after instillation, reaches a maximum after 2-6 hours and lasts 24 hours. Does not affect accommodation, refraction and pupil size.

Special instructions

During treatment with the drug, wearing soft contact lenses is not recommended. When using hard lenses, you should remove them before instillation and put them back on 15-20 minutes after instillation of the drug.

Patients who temporarily lose clarity of vision after instillation are not recommended to drive a car or work with complex machinery, machines or any other complex equipment that requires clarity of vision immediately after instillation of the drug.

The dropper tube must be closed after each use. Do not touch the tip of the dropper tube to your eye.

Composition

Active ingredients:
butylaminohydroxypropoxyphenoxymethyl methyloxadiazole – 10.00 mg,
Clonidine hydrochloride hydrochloride (clonidine) – 2.50 mg
Excipients:
benzethonium chloride – 0.10 mg,
sodium chloride – 6.00 mg,
citric acid monohydrate (or citric acid – 0.33 mg, calculated as citric acid monohydrate)
sodium citrate dihydrate – 5.34 mg,
equivalent to 6.49 mg of sodium citrate pentasesquihydrate, water for injection – up to 1 ml.

Pregnancy

During pregnancy, it is necessary to weigh the benefits for the mother against the risks for the fetus and newborn. It is not known whether the drug passes into breast milk, therefore, during lactation, during treatment, it is recommended to discontinue breastfeeding.

Contraindications

– individual hypersensitivity to the components of the drug;
– bronchial asthma;
– chronic obstructive pulmonary disease;
– chronic heart failure;
– bradycardia;
– atrioventricular block II-III stage;
– arterial hypotension;
– pregnancy;
– children’s age (there is no sufficient experience in using the drug in children).

With caution
Diabetes mellitus type 1, peptic ulcer of the stomach and duodenum.

Side Effects

In isolated cases, the following are possible: decreased blood pressure, slowed heart rate, dry mouth, drowsiness, weakness, dizziness, but to a lesser extent than from the use of clonidine alone.

Interaction

Combined use with a 1% solution of pilocarpine causes an additional hypotensive effect on the level of intraocular pressure (IOP).

With simultaneous administration of systemic alpha or beta blockers, the hypotensive effect may be enhanced.

Storage conditions

In a place protected from light at a temperature not exceeding 15 °C.

Keep out of the reach of children.

Shelf life

The shelf life of the drug after opening is 1 month.

Do not use after the expiration date stated on the package.

Manufacturer

Moscow Endocrine Plant, Russia